TRMOY vs ASND
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TRMOY · TOURMALINE OIL CORP UNSPON ADS EACH REP 0.3 COM$15.00 ▼ 6.25%
ASND · Ascendis Pharma A/S$256.82 ▲ 1.33%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TRMOY +8.0%
- ASND -3.2%
Head to head
| Metric | TRMOY | ASND |
|---|---|---|
| Price | $15.00 | $256.82 |
| Change today | ▼ 6.25% | ▲ 1.33% |
| Market cap | $16.90B | $16.90B |
| Return, 3 months | -23.5% | +0.5% |
| Return, year to date | – | +20.4% |
| Return, 1 year | – | +23.3% |
| P/E (TTM) | 30.0 | 20.5 |
| P/B | 1.5 | 10.5 |
| P/E percentile vs own 5y | – | 94th |
| Dividend yield | 2.36% | – |
| Revenue growth (YoY, latest qtr) | – | +114.7% |
| Net profit growth (YoY) | – | +632.7% |
| Gross margin | – | 91.3% |
| Operating margin | – | 25.1% |
| Net margin | – | 70.8% |
| Return on equity | – | 118.8% |
| Analyst target vs. price | – | +21.0% |
| Analyst buy share | – | 94% |
| RSI (14) | 45 | 65 |
| 30-day volatility | 41.9% | 22.4% |
| Max drawdown, 1 year | -26.9% | -19.7% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TRMOY is the largest of the group by market value.
- ASND carries the lowest trailing P/E.
- ASND has been the calmest stock over the last 30 days.